Trang chủ

Tài liệu nghiên cứu Y học

Search Journal

Search Article

Search by Auth

Category

From

To

Investigational New Drugs

Volume 37, June 2019, Issue 3, Pages 401-593

Previous vol/issue

Next vol/issue

1. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC

Tác giả

Enxin Wang, Dongdong Xia, Wei Bai, Zhexuan Wang, Qiuhe Wang.

2. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro

Tác giả

.

3. Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation

Tác giả

Su Myat Phyu, Tim A. D. Smith.

4. Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model

Tác giả

Martin Perreault, René Maltais, Jenny Roy, Sylvain Picard.

5. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

Tác giả

Alexandra Canonici, Laura Ivers, Neil T. Conlon.

6. A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2

Tác giả

Hui Huang, Junxing Niu, Fei Wang, Lihong Hu, Qiang Yu.

7. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

Tác giả

Antonio Jimeno, Kathleen N. Moore, Michael Gordon.

8. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer

Tác giả

Amit Mahipal, Sri Harsha Tella, Anuhya Kommalapati.

9. Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer

Tác giả

G. Weldon Gilcrease, David D. Stenehjem, Mark L. Wade.

10. Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials Audrey

Tác giả

E. Kam, Gopichand Pendurti, Umang H. Shah.

11. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens

Tác giả

J. R. Goffin, G. Nicholas, M. Mates, D. Tu, E. Chen.

12. First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

Tác giả

Toshihiko Doi, Kiyotaka Yoh, Kohei Shitara, Hideaki Takahashi.

13. Increasing complexity in oncology phase I clinical trials Laeeq

Tác giả

Malik, David Lu.

14. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer

Tác giả

Giandomenico Roviello, Roberto Petrioli, Pietro Rosellini.

15. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma

Tác giả

Norimichi Akiyama, Masato Karayama, Naoki Inui, Hideki Yasui.

16. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Tác giả

Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo.

17. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma

Tác giả

M. Christina Cox, Sabrina Pelliccia, Luigi Marcheselli.

18. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer

Tác giả

Vadim S. Koshkin, Maria C. Mir, Pedro Barata, Anita Gul.

19. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

Tác giả

Changhoon Yoo, Joong-Won Park, Yoon Jun Kim, Do Young Kim.

20. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study

Tác giả

Hanae Ida, Yoshitaka Honma, Hidekazu Hirano, Hirokazu Shoji.

21. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review

Tác giả

Hyeon Cheun, Miso Kim, Hajeong Lee, Kook-Hwan Oh, Bhumsuk Keam.

22. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores

Tác giả

Inhwan Hwang, Jihoon Kang, Hei Nga Natalie Ip, Jae Ho Jeong.

23. Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Tác giả

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao.

24. Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial Correction to: Eribulin, trastuzumab, and pe

Tác giả

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito